Get the Daily Brief
Latest Biotech News
Vertex acquisition of Crinetics
Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals in a $10 billion deal that marks the biggest acquisition in its history and adds endocrine disease to its commercial pillars. The...
FDA approval for IgA nephropathy: Vera Therapeutics Trutakna
The FDA granted accelerated approval to Vera Therapeutics’ Trutakna (atacicept) for immunoglobulin A nephropathy (IgAN), clearing a weekly, auto-injector therapy as the first dual BAFF/APRIL...
Novartis ADC push via Myricx Bio purchase
Novartis agreed to acquire Myricx Bio, paying $1.1 billion upfront and up to $400 million in milestones for the UK biotech’s next-generation antibody-drug conjugate (ADC) payload platform. The...
MeiraGTx gene therapy funding and monetization structure
Oberland Capital agreed to invest up to $400 million into MeiraGTx to support commercialization readiness for its late-stage gene therapy pipeline, including programs previously reacquired from...
Gene therapy trial alignment: Opus Genetics with FDA for phase III
Opus Genetics reached FDA alignment on an eight-patient phase III trial of its inherited childhood blindness gene therapy candidate, OPGx-LCA5. The company said the regulatory alignment supports...
Micro-needle-like platform financing: EG427/‘EG427’ series C
Formerly known as EG427, the gene therapy specialist closed a €33 million (about $37.7 million) Series C to advance its lead program in chronic neuro-urology indications. The funding comes as the...
Bristol Myers confirms Krazati confirmatory trial failure in colorectal cancer
Bristol Myers Squibb disclosed that its confirmatory phase 3 Krystal-10 trial of Krazati (adagrasib) plus cetuximab failed to meet dual primary endpoints in previously treated KRAS G12C-mutated...
Kailera obesity pill late-stage success and safety signal
Kailera Therapeutics said its obesity drug met efficacy goals in late-stage China trials, reporting about 10% weight loss over 10 months. The company’s data also showed high rates of...
Twist Bioscience stock rating downgrade amid AI revenue debate
Evercore ISI downgraded Twist Bioscience shares to In Line from Outperform and set a $102 price target, citing that the stock has already run up sharply this year. The analyst pointed to concerns...
Chinese trial scrutiny: US lawmakers target clinical research in military hospitals and Xinjiang
A U.S. House Select Committee on China investigation is examining clinical trials conducted at Chinese military hospitals and in Xinjiang involving U.S. companies. The probe adds compliance and...
Vertex expands endocrinology footprint with Crinetics buyout
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, its largest-ever deal, to deepen a commercial endocrinology portfolio. Vertex will pick up Crinetics’ launched...
Bristol Myers confronts Krazati confirmatory setback in colorectal cancer
Bristol Myers Squibb disclosed that the confirmatory phase 3 Krystal-10 trial of Krazati (adagrasib) plus Eli Lilly’s Erbitux (cetuximab) failed to hit statistical significance in KRAS...
Novartis scales differentiated ADC payload platform with Myricx deal
Novartis agreed to pay $1.1 billion upfront to acquire Myricx Bio, adding a preclinical antibody-drug conjugate payload platform built on N-myristoyltransferase (NMT) inhibitors. The Swiss pharma...
Kailera/Hengrui deliver Phase 3 toplines for oral GLP-1 in China
Kailera Therapeutics said its oral GLP-1 asset achieved primary endpoints in two Phase 3 obesity and diabetes trials in China, supporting Hengrui Pharma’s path to regulatory submissions. The...
Whitehawk expands ADC pipeline through Biocytogen bispecific licensing
Whitehawk Therapeutics entered a development deal with China-headquartered Biocytogen to build bispecific antibody-drug conjugates. The collaboration grants Whitehawk access to five...
Boehringer licenses ORFV viral vector platform for next-gen cancer vaccines
Boehringer Ingelheim secured an exclusive license to Prime Vector Technologies’ viral vector platform for cancer vaccine research. The deal covers use of Prime Vector’s Orf virus (ORFV)...
Regulatory action: Thermo Fisher wins FBI NDIS approval for rapid DNA profiling
Thermo Fisher Scientific received FBI National DNA Index System (NDIS) approval for its Applied Biosystems RapidIntel Plus cartridge used with the RapidHit ID system for rapid DNA profiling of...
Drug safety signal management: Abivax shares gain after UC data reassures investors
Abivax’s obefazimod rallied after new clinical data in its Phase 3 ulcerative colitis program reassured investors on benefit and tolerability. The company said ABTECT Maintenance Part 2 showed...
Clinical trial integrity spotlight as China-led study retractions raise transparency questions
The retraction of a high-profile China-led lung cancer paper put data transparency under renewed scrutiny as U.S. lawmakers and industry debate the validation systems behind fast-moving clinical...
Carve-out of evidence on research misconduct incentives: China paper retraction ecosystem
A new report ties China’s spate of research retractions to incentive structures that reward publication volume and citation metrics, according to comments from Retraction Watch co-founder Ivan...